Aptevo Therapeutics Inc. financial data

Symbol
APVO on Nasdaq
Location
Seattle, WA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 217% % 6.2%
Debt-to-equity 145% % -13%
Return On Equity -389% % -12%
Return On Assets -159% % -22%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 16,850,494 shares -9%
Common Stock, Shares, Outstanding 13,808,966 shares -19%
Entity Public Float $1,200,000 USD -89%
Common Stock, Value, Issued $110,000 USD 34%
Weighted Average Number of Shares Outstanding, Basic 4,049,046 shares 28306%
Weighted Average Number of Shares Outstanding, Diluted 4,049,046 shares 28306%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $14,885,000 USD 5.7%
General and Administrative Expense $11,813,000 USD 12%
Operating Income (Loss) $26,698,000 USD -8.5%
Net Income (Loss) Attributable to Parent $26,473,000 USD -12%
Earnings Per Share, Basic 1,860 USD/shares 99%
Earnings Per Share, Diluted 1,860 USD/shares 99%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $21,061,000 USD 172%
Other Assets, Current $77,000 USD -88%
Assets, Current $22,649,000 USD 126%
Property, Plant and Equipment, Net $384,000 USD -37%
Operating Lease, Right-of-Use Asset $3,963,000 USD -12%
Assets $26,996,000 USD 78%
Employee-related Liabilities, Current $1,901,000 USD 106%
Liabilities, Current $5,614,000 USD -4.6%
Operating Lease, Liability, Noncurrent $3,990,000 USD -17%
Other Liabilities, Noncurrent $0 USD
Liabilities $9,604,000 USD -10%
Retained Earnings (Accumulated Deficit) $269,217,000 USD -12%
Stockholders' Equity Attributable to Parent $17,392,000 USD 293%
Liabilities and Equity $26,996,000 USD 78%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $6,575,000 USD 1.1%
Net Cash Provided by (Used in) Financing Activities $0 USD
Common Stock, Shares Authorized 500,000,000 shares 0%
Common Stock, Shares, Issued 13,808,966 shares -19%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $6,575,000 USD 1.2%
Deferred Tax Assets, Valuation Allowance $49,180,000 USD -7.6%
Deferred Tax Assets, Gross $50,102,000 USD -7.6%
Operating Lease, Liability $5,398,000 USD -11%
Lessee, Operating Lease, Liability, to be Paid $7,339,000 USD -16%
Property, Plant and Equipment, Gross $14,488,000 USD 0%
Operating Lease, Liability, Current $800,000 USD 14%
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,376,000 USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,376,000 USD 0%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1,941,000 USD -26%
Lessee, Operating Lease, Liability, to be Paid, Year Three $1,376,000 USD 0%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 15,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Operating Lease, Payments $344,000 USD 0%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $61,000 USD -42%
Deferred Tax Assets, Net of Valuation Allowance $922,000 USD -10%
Share-based Payment Arrangement, Expense $530,000 USD -73%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%